The QualityStocks Daily Friday, October 20th, 2023

Today's Top 3 Investment Newsletters

SmallCapRelations(PBIO) $0.6300 +50.00%

QualityStocks(ELTP) $0.1384 +39.52%

MarketClub Analysis(LIPO) $2.0900 +29.81%

The QualityStocks Daily Stock List

Elite Pharmaceuticals (ELTP)

QualityStocks, Stockpalooza, PennyTrader Publisher, OTCPicks, PennyStocks24, MarketBeat, Real Pennies, Capital Equity Report, MadPennyStocks, Marketbeat.com, PennyStock MarketBulls, SmarTrend Newsletters, RagingStock Bull, PennyInvest, OTCBB Journal, Greenbackers, First Penny Picks, Pennybuster, TopPennyStockMovers, StockEgg, Stock Analyzer, Top Stock Picks, StockRich, StocksImpossible, TheMicrocapNews, HotStockChat, HotOTC, PennyStockProphet, FeedBlitz, OTC Advisors, CRWEPicks, CoolPennyStocks, Wise Alerts, Buzz Stocks, BullRally, Beacon Equity Research, GoldminePennyStocks, Alternative Energy, SmallCap Network, Pumps and Dumps, Promotion Stock Secrets, Planet Penny Stocks, SmallCapVoice, PennyStockVille, MarketClub Analysis, Stock Fortune Teller, MicrocapVoice, Stock Preacher, Penny Stock Rumble, Penny Pick Finders, Penny Invest, StockOnion, SecretStockPromo and WiseAlerts reported earlier on Elite Pharmaceuticals (ELTP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elite Pharmaceuticals Inc. (OTCQB: ELTP) is a pharmaceutical firm that is focused on conducting research on, developing, manufacturing and licensing drug delivery products and systems.

The firm’s headquarters are in the state of New Jersey, United States and was incorporated in 1997, on October 1st. It operates as part of the healthcare industry, under the biotech and pharma sub-industry. The firm serves consumers around the globe.

The company is party to a strategic marketing alliance with Lannett Company Inc. and Glenmark Pharmaceuticals Inc. It is also party to a development and license agreement with SunGen Pharma LLC.; and a manufacturing and license agreement with Epic Pharma LLC. The company operates through the New Drug applications for branded and generic products.

The enterprise’s products include Isradipine capsules for cardiovascular ailments; Naltrexone tablets for pain management; Phendimetrazine Tartrate tablets for bariatrics; and HydromorphoneHCl tablets for pain. It also offers Methadone HCl tablets for pain; Trimipramine Maleate Immediate Release antidepressant capsules; Amphetamine sulfate immediate release, Dextroamphetamine sulfate and Dextroamphetamine saccharate tablets for central nervous system diseases. In addition to this, the enterprise manufactures controlled-release products on a contract basis for 3rd parties, in the areas of infection, bariatric, allergy and pain. The enterprise is also focused on the development of a range of abuse deterrent opioid products.

The firm recently released it latest financial results for the year 2021, which show increases in its revenues and profits. Currently, it is focused on diversifying its products in order to stabilize the firm and support its growth.

Elite Pharmaceuticals (ELTP), closed Friday's trading session at $0.1384, up 39.5161%, on 5,317,184 volume. The average volume for the last 3 months is 11.185M and the stock's 52-week low/high is $0.0269/$0.14.

Aravive Inc. (ARAV)

MarketBeat, TradersPro, StockMarketWatch, InvestorPlace, QualityStocks, MarketClub Analysis, TopPennyStockMovers, StreetInsider and BUYINS.NET reported earlier on Aravive Inc. (ARAV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aravive Inc. (NASDAQ: ARAV) is a clinical-stage biopharmaceutical firm that is focused on the development of treatments for life-threatening ailments with a focus on hematologic malignancies and various cancers.

The firm has its headquarters in Houston, Texas and was incorporated in 2008, on December 10th. Prior to its name change in October 2018, the firm was known as Versartis Inc. It mainly serves consumers in the United States.

The company is party to a license agreement with 3D Medicines Inc. which entails the development of products that contain its AVB-500 product as the single drug substance for the treatment of human oncological ailments in Macau, Hong Kong, Taiwan and mainland China. It is also party to a strategic collaboration agreement with WuXi Biologics which entails the development of new high-affinity bispecific antibodies that target fibrosis and cancer.

The enterprise’s product portfolio comprises of a soluble Fc-fusion protein dubbed AVB-S6 which blocks the activation of the GAS6-AXL signaling pathway. It also produces a decoy protein dubbed AVB-500 which targets the GAS6-AXL pathway. The protein is currently in a phase 2b/3 clinical trial evaluating its effectiveness in treating platinum-resistant recurrent ovarian cancer, as well as non-small-cell lung cancers, urothelial, pancreatic cancer, uterine, HER negative breast cancers and clear renal cell carcinoma.

The company is focused on advancing its AVB-500 formulation as a treatment for pancreatic adenocarcinoma. The success and approval of this formulation for this particular indication would meet significantly unmet medical needs for patients, which will not only benefit them but also bring in more investors into the firm, which would boost the company’s growth.

Aravive Inc. (ARAV), closed Friday's trading session at $0.1855, up 31.7472%, on 112,612,053 volume. The average volume for the last 3 months is 6,510 and the stock's 52-week low/high is $0.11/$2.46.

Huaneng Power (HUNGF)

MarketBeat reported earlier on Huaneng Power (HUNGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Huaneng Power International Inc. (OTC: HUNGF) (HKG: 0902) (SHA: 600011) (FRA: HUP1) is a company focused on generating and selling electric power to the regional or provincial grid firms.

The firm has its headquarters in Beijing, China and was incorporated in 1994, on June 30th. It operates as part of the utilities-independent power producers industry, under the utilities sector. The firm serves consumers around the globe, with a focus on those in the People’s Republic of China.

The enterprise generates power from hydro, gas turbine, wind, photovoltaic, coal-fired and biomass resources. It is also involved in cargo loading and storage; sale of coal ash and lime; port, warehousing, and conveying activities; and provision of thermal energy and cold energy services. This is in addition to offering thermal heating services; repairing and maintaining power equipment; plumbing pipe installation and repair; supply of steam and hot water; and energy engineering construction activities. Further, the enterprise provides construction and operation of electricity distribution networks and heating pipe networks; cargo handling and transportation; port management, investment, and development activities and transportation services. It also offers central heat and desalinated water services; and sells raw and processed coal. As of December 2022, the enterprise had a controlled installed capacity of 127,228 megawatts and low carbon clean energy installed capacity of 33,171 MW. Its domestic power plants are in 26 provinces, autonomous regions and municipalities. It also wholly owns an operating power company in Singapore and invests in a power company in Pakistan.

The company remains committed to providing environmentally friendly and affordable energy to society while also creating long-term, stable and growing returns for its shareholders.

Huaneng Power (HUNGF), closed Friday's trading session at $0.4296, off by 1.6655%, on 31,153 volume. The average volume for the last 3 months is 175,148 and the stock's 52-week low/high is $0.3308/$0.66735.

Guanajuato Silver (GSVRF)

We reported earlier on Guanajuato Silver (GSVRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Guanajuato Silver Company Ltd (OTCQX: GSVRF) (CVE: GSVR) (FRA: E35) is a metal mining firm focused on acquiring, exploring for, developing and evaluating mineral assets in Mexico and Canada.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1978, on August 11th. Prior to its name change in June 2021, the firm was known as Vangold Mining Corp. It operates as part of the silver industry, under the basic materials sector. The firm mainly serves consumers in Canada.

The company primarily explores for gold, silver, lead and zinc. It produces silver and gold concentrates from the El Cubo Mine, Valenciana Mines Complex and the San Ignacio mine, which are located within the state of Guanajuato; and silver, zinc, gold and lead concentrates from the Topia mine located in northwestern Durango. The El Cubominr has 45,000 tons per month capacity, a high-grade epithermal-vein underground mine and pure precious metal producer (silver and gold). The world’s largest silver producer in the 18th century, the Valenciana Mine complex, has been in production since the 1500s. On the other hand, the Topia mine produces a lead-silver-gold concentrate and a separate zinc concentrate. The company conducts business through its four operating mines and three processing facilities.

The enterprise recently released its latest financial results, with its CEO noting that they had made progress in bringing its newly purchased mining assets into optimal production. It remains committed to delivering improved efficiencies and prioritizing cost controls. This may, in turn, influence production and revenues positively.

Guanajuato Silver (GSVRF), closed Friday's trading session at $0.227, up 3.8426%, on 317,223 volume. The average volume for the last 3 months is 130,005 and the stock's 52-week low/high is $0.1812/$0.488.

AmmPower (AMMPF)

We reported earlier on AmmPower (AMMPF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AmmPower Corp. (OTCQB: AMMPF) (CNSX: AMMP) (FRA: 601A) is a clean energy firm that is focused on manufacturing and selling green ammonia to farmers, distributors and retailers of anhydrous ammonia used in fertilizer.

The firm has its headquarters in Toronto, Canada and was incorporated in 2019, on December 3rd. Prior to its name change in April 2021, the firm was known as Soldera Mining Corp. It operates as part of the gold industry, under the basic materials sector. The firm mainly serves consumers in the United States and Canada.

The company is active in all facets of green ammonia technology, including the production of green fertilizers, carbon-free shipping fuel, and the cracking or moving of green hydrogen as ammonia. It is developing technologies to produce green ammonia and green hydrogen at scale. The company is manufacturing its Independent Ammonia Making Machine (IAMM) units to create green ammonia for the agricultural industry.

The enterprise holds a lithium exploration property in Quebec and an option on the Titan Property located in Northwestern Ontario. The Titan Gold Property comprises of about 34 mineral tenures and is located in the Klotz Lake Area in Northwestern Ontario. The Whabouchi Property is located in the James Bay/Eeyou Istche region of Quebec.

The firm recently announced that a new ammonia synthesis converter technology designed for small production units had been granted a utility patent by the United States Patent and Trademark Office. This success reflects its commitment to staying at the forefront of technological advancements, which may positively influence investments into the firm.

AmmPower (AMMPF), closed Friday's trading session at $0.062, up 8.0554%, on 83,138 volume. The average volume for the last 3 months is 532 and the stock's 52-week low/high is $0.05/$0.3116.

Genting BHD (GEBHF)

Uncommon Wisdom reported earlier on Genting BHD (GEBHF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Genting Berhad (OTC: GEBHF) (OTC: GEBHY) (KLSE: GENTING) is an investment holding firm focused on the leisure and hospitality, entertainment and gaming, electric power generation and supply, plantation, property development and management, biotechnology, investments and oil and gas exploration businesses globally.

The firm has its headquarters in Kuala Lumpur, Malaysia and was incorporated in 1965 by Goh Tong Lim. It operates as part of the resorts and casinos industry, under the consumer cyclical sector. The firm primarily serves consumers in Malaysia and Singapore.

The company’s Leisure & Hospitality business is involved in gaming, hotels, food and beverages, theme parks, retail, entertainment and attractions, and tours and travel-related businesses; the development and operation of resorts; and the provision of other support services. Its Power segment generates and supplies electric power while the Plantation segment operates oil palm plantations, and palm oil milling and related activities. The company's Property segment develops and invests in properties while its Oil & Gas segment explores for, develops, and produces oil and gas. In addition to this, it manufactures and sells biodiesel; provides project management, technical, and other management services; creates a platform for the early diagnosis and treatment of Alzheimer's and other neurodegenerative illnesses; processes fresh fruit bunches; and develops rapid sequencing-based diagnostic tests. Furthermore, the company researches and develops for the genomics, natural sciences’ and engineering faculties; offers information technology services relating to the gaming and resort industry; and provides plant screening services.

The enterprise, which recently released its latest financial results, remains committed to enhancing shareholder value and maintaining long-term sustainable growth in its core businesses.

Genting BHD (GEBHF), closed Friday's trading session at $0.965, even for the day. The average volume for the last 3 months is 8,561 and the stock's 52-week low/high is $0.70/$1.206358.

Bitterroot Resources (BITTF)

We reported earlier on Bitterroot Resources (BITTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bitterroot Resources Ltd (OTC: BITTF) (CVE: BTT) is an exploration-stage firm that is focused on acquiring, developing, exploring for and evaluating mineral properties in the United States.

The firm has its headquarters in West Vancouver, Canada and was incorporated in 1951, on March 13th. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers in the United States and Canada.

The company primarily explores for copper, gold, nickel, silver and PGM deposits. It holds 100% interest in the LM Property, a nickel-copper-platinum-palladium deposit in the Upper Peninsula of Michigan. The property covers an area of 40 acres situated in Baraga County and has approximately 26 core holes totaling 7,565 meters. It also holds interests in the Voyageur Lands property, which covers about 360 miles2 in the Upper Peninsula of Michigan; and the Coyote Sinter Gold property, which comprises of roughly 49 unpatented claims located on BLM-administered land in Elko County, Nevada. The Coyote Sinter Gold property hosts a low sulfidation epithermal system. In addition to this , it holds interests in the Castle West property, which includes 34 unpatented mining claims and 3 leased unpatented claims that cover an area of about 282 hectares located in western Nevada's Gilbert mining district.

The enterprise, together with Altius Minerals Corporation, recently entered into an option agreement with Perseverance Metals Inc. which will allow Perseverance to acquire 100% interest in the Voyageur Nickel-Copper-PGM Project. This move’s success will rapidly advance said project and provide exposure to other high-quality magmatic nickel projects.

Bitterroot Resources (BITTF), closed Friday's trading session at $0.02, even for the day. The average volume for the last 3 months is 380,825 and the stock's 52-week low/high is $0.016/$0.043.

Verano Holdings Corp. (VRNOF)

QualityStocks, MarketBeat, The Street, InvestorPlace and Early Bird reported earlier on Verano Holdings Corp. (VRNOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent New Jersey poll has revealed that people are increasingly noticing the smell of marijuana more than a year into cannabis legalization. However, many residents seem to be unbothered by the often pungent smell, and even more believe that drunk driving is “very dangerous’” in comparison to driving under the influence of marijuana.

The Stockton University’s Hughes Center for Public Policy poll found that 31% of the respondents believed that cannabis use laws superseded the right to not smell marijuana from a neighbor’s house. The study also reported that 46% of respondents said both rights were of equal importance while 16% believed the right to not smell cannabis from neighbors was more important than cannabis use laws.

However, even though cannabis users in New Jersey have legal means for accessing the drug, only 14% of New Jersey residents said they smelled cannabis from neighboring houses often, 15% said they sometimes smell the controversial drug and 21% reported that they rarely smelled cannabis from their neighbors.

Conversely, 57% of adults in New Jersey said they have smelled cannabis in public since legalization, with 29% saying they catch the smell often and 28% saying they catch it sometimes. An estimated 31% of the respondents said they rarely smell cannabis while out in public, and 9% said they have never smelled marijuana in public.

Hughes Center director John Froonjian said that while there was much excitement about the legalization of recreational cannabis in New Jersey, policymakers didn’t put a lot of thought into the issue of public cannabis use. Without any legal places for people to consume their cannabis, many people are opting to consume the drug at festivals, on the streets, in parking lots and in parks.

Given marijuana’s extremely pungent smell, burning cannabis is quite distinctive, and the aromatic odors from the substance can travel for up to 82 feet before fully dissipating. A whopping 90% of respondents said they could identify the smell of cannabis while 52% said they had zero issues with the smell. Another 28% reported being “somewhat” bothered by the smell, and 19% said that the pungent aroma bothered them “a great deal.”

Unsurprisingly, 55% of people who consumed cannabis said one’s right to use cannabis at home overrode a neighbor’s right to not smell the plant in their residence while only 21% of noncannabis users had the same opinion. In addition, 75% of users and 91% of nonusers said that driving while under the influence of cannabis was dangerous, while 52% of consumers and 81% of nonconsumers said they supported roadside tests to determine driver impairment levels.

This huge enthusiasm for marijuana in New Jersey is likely to give rise to successful companies along the lines of Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) and other companies thriving in other legal cannabis markets in the U.S.

Verano Holdings Corp. (VRNOF), closed Friday's trading session at $4.425, off by 1.8325%, on 61,785 volume. The average volume for the last 3 months is 3.043M and the stock's 52-week low/high is $2.53/$6.08.

Bit Digital Inc. (BTBT)

QualityStocks, StocksEarning, MarketClub Analysis, Schaeffer's, TradersPro, InvestorPlace, StockEarnings, MarketBeat, InvestorsUnderground, Daily Trade Alert and CryptoCurrencyWire reported earlier on Bit Digital Inc. (BTBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ferrari has begun to take crypto payments for its luxury sports cars in the United States and will expand the program to Europe at the behest of its wealthy clientele. According to Enrico Galliera, Ferrari’s head of marketing, cryptos have demonstrated their commitment to reducing their environmental footprint through the adoption of novel software and relying more heavily on renewable energy. He also asserted Ferrari’s commitment to carbon neutrality throughout its value chain by 2030.

Most corporations have maintained a cautious stance toward cryptocurrencies due to their inherent volatility, rendering them unsuitable for conventional commerce. Additionally, inconsistent regulations and the considerable energy consumption associated with crypto have been formidable barriers to its widespread adoption as a payment method.

While some cryptocurrencies have made strides in enhancing their energy efficiency, Bitcoin, the largest of them all, remains under scrutiny for its energy-intensive mining process.

Galliera stated that the company’s decision to embrace cryptocurrency payments emerged from the collective voices of the market and the company’s dealers, who have increasingly invested in crypto. Ferrari, which dispatched more than 1,800 vehicles to its Americas market in the first half of this year, refrained from specifying the number of vehicles it anticipates selling through crypto. Currently, the company boasts a robust order backlog extending into 2025 and hopes to get more clients through the new crypto payment method.

The Italian automaker plans to expand its crypto payment program to Europe by March next year, with further plans to extend it to other territories where crypto transactions are legally permissible. The company has partnered with BitPay, a major crypto payment processor, for the initial phase of the initiative in the United States. Transactions can be conducted using USDC, Ethereum and Bitcoin. Ferrari intends to collaborate with more payment processors as the program expands globally.

Galliera stated that clients would not incur any additional surcharges or fees when using cryptocurrency. BitPay will serve as the intermediary, instantly converting crypto payments into conventional currency, thereby safeguarding both Ferrari’s dealers and the company itself from the price fluctuations inherent to the cryptocurrency market.

Furthermore, BitPay will undertake the essential role of ensuring that all cryptocurrency funds come from secure and legitimate sources, precluding any association with money laundering, tax evasion or any other illicit activities. Galliera reported that most of its American dealers have already joined the initiative or are in the process of doing so, demonstrating their confidence in the success of crypto payments. The company anticipates more will soon follow suit.

This announcement by Ferrari is most likely good news for crypto industry actors such as Bit Digital Inc. (NASDAQ: BTBT) since it adds to the credibility of digital currencies.

Bit Digital Inc. (BTBT), closed Friday's trading session at $2.07, up 4.0201%, on 3,839,032 volume. The average volume for the last 3 months is 327,050 and the stock's 52-week low/high is $0.5301/$4.795.

Compass Minerals International Inc. (CMP)

SmarTrend Newsletters, QualityStocks, MarketBeat, The Online Investor, Daily Trade Alert, Trades Of The Day, DividendStocks, Marketbeat.com, The Street, InvestorPlace, Kiplinger Today, MiningNewsWire, Zacks, StreetAuthority Daily, Schaeffer's, StreetInsider, All about trends, MarketClub Analysis, The Stock Dork, Insider Wealth Alert, Top Pros' Top Picks, Daily Wealth, Wyatt Investment Research, Daily Market Beat, CRWEFinance, BUYINS.NET and Barchart reported earlier on Compass Minerals International Inc. (CMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

With global fertilizer costs soaring to historic highs in recent years, the Japanese government is considering using recycled human waste as an alternative to conventional fertilizers. The ongoing Russia-Ukraine war has had massive global repercussions, including a severe fertilizer shortage, which has caused international fertilizer prices to spike.

In 2021 alone, Russia exported a whopping 11.8 metric million tons of muriate of potash (MOP); 7 million metric tons of urea; 5.93 million metric tons of nitrogen, phosphorus, and potassium fertilizers; and 4.32 million metric tons of ammonium nitrate. Russia and Ukraine together provide around 28% of the world’s potassium phosphorus, and nitrogen fertilizers and the ongoing war has significantly affected global supplies, forcing countries such as Japan that rely on fertilizer imports to find alternative sources.

With Japan’s history of using human waste as fertilizer, it is not surprising that the nation is turning back to old knowledge to fill current fertilizer supply gaps. Throughout the nation’s early modern period, farmers living on the fringe of urban areas would purchase human waste from cities and use it to fertilize their plants.

Called “night soil,” the use of human waste fell out of practice as sewage systems and treatment facilities became more prevalent across the country. However, there has been interest in reviving the old agricultural technique in Japan for at least a decade, and the Russia-Ukraine war significantly increased interest in the idea as fertilizer imports became more costly.

One Japanese treatment facility began producing human waste fertilizer in 2010 but saw demand for its product increase by 160% year-over-year earlier this year. According to facility vice president Toshiaki Kato, the company’s fertilizer is in demand because it is cheap and can help customers reduce their costs in an era where farming is becoming increasingly expensive. On top of that, Kato says, converting human waste into fertilizers is “good for the environment.”

Sewage sludge disposal, which is the usual way Japan deals with human waste, especially in urban areas, is incredibly expensive and damaging to the environment. The fertilizer is produced from the combination of human waste collected from cesspits and treated sewage sludge sourced from septic tanks. The resulting product is called shimogoe and sells for $1.10 (160 yen) per 33 pounds, one-tenth of the cost of imported fertilizers.

Officials in southwestern Japan say human waste fertilizer sales are up by two to three times, and groups from several municipalities have visited the region to learn from the program and replicate it in their own communities.

Conventional fertilizer manufacturers such as Compass Minerals International Inc. (NYSE: CMP) have their work cut out to ensure adequate supplies of fertilizers on the global market at affordable prices despite the ongoing geopolitical tensions and wars.

Compass Minerals International Inc. (CMP), closed Friday's trading session at $26.78, off by 1.0713%, on 337,592 volume. The average volume for the last 3 months is 441,606 and the stock's 52-week low/high is $25.8462/$47.68.

Mind Medicine Inc. (MNMD)

QualityStocks, InvestorPlace, Schaeffer's, The Wealth Report, The Street, MarketBeat, The Stock Dork, MarketClub Analysis, Daily Trade Alert and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Recent study findings published in the “Substance Use & Misuse” journal indicate that the use of psychedelics such as LSD is becoming especially prevalent among business managers in managerial positions. The study found that while there has been a general increase in psychedelic interest in the public, company executives seem to be using lysergic acid diethylamide (LSD) at high rates.

Psychedelics have enjoyed significant attention from public and scientific circles in recent years thanks to a growing body of research connecting hallucinogens such as LSD, psilocybin, ayahuasca and MDMA to a wide range of mental health benefits. Research has found that psychedelics can offer relief against a myriad of mental-health conditions with few, if any, adverse side effects.

With millions of Americans facing conditions such as anxiety, eating disorders, depression and post-traumatic stress disorder (PTSD), the country is in desperate need of safe and effective mental-health treatments. Based on the research available so far, psychedelics may have the potential to revolutionize psychiatry and significantly improve treatment outcomes for millions of people across the country.

Study author and University of Bamberg postdoctoral researcher Benjamin Korman says there has been a dramatic rise in anecdotal media reports of employees and business leaders using psychedelics. As such, the study’s aim was to determine whether the media reports actually represented a shift in workplace psychedelic use or were based on skewed reporting.

Korman analyzed data from the annual National Survey on Drug Use and Health (NSDUH), a rich information source that provided data on adults aged 18 years old and older with full-time jobs from 2006 to 2014. Analysis of data from more than 168,000 full-time employees revealed that there has been a steady increase in psychedelic use among full-time workers.

After accounting for managerial status, income, education attainment, gender, age and prior substance use, the researcher found that there was a dramatic rise in psychedelic use among male and female business managers. Compared to nonmanagers who saw a 0.02% annual bump in past-year LSD use, managers saw a 0.07% increase in LSD use.

Korman said that while prior research had pointed to increased psychedelic use among young American adults, his study indicated that board rooms and C-suites were also experiencing a notable rise in psychedelic use. LSD use among managers surpassed past-year use by nonmanagers in 2014 when there was an almost 1,100% rise in LSD use among the manager class, Korman notes.

This growing self-prescription of psychedelics creates more urgency for entities such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) to commercialize approved psychedelic formulations so that those who need them can access them through their doctors.

Mind Medicine Inc. (MNMD), closed Friday's trading session at $2.62, off by 2.6022%, on 243,114 volume. The average volume for the last 3 months is 31.802M and the stock's 52-week low/high is $2.12/$5.01.

Tilray Brands Inc. (TLRY)

Schaeffer's, InvestorPlace, The Street, StocksEarning, StockEarnings, MarketClub Analysis, MarketBeat, QualityStocks, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Kiplinger Today, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, BUYINS.NET, Zacks, Investopedia, CFN Media Group, CNBC Breaking News, Early Bird, The Street Report, Daily Profit, INO Market Report, StreetAuthority Daily, Inside Trading, The Rich Investor, Tip.us, Top Pros' Top Picks, FreeRealTime, InvestmentHouse, Trading For Keeps, Trading Concepts, Eagle Financial Publications, InvestorsObserver Team, Investors Alley, Investment House, Outsider Club, wyatt research newsletter, Wealth Daily, VectorVest, TheTradingReport, The Night Owl, StrategicTechInvestor, Money Morning, Rick Saddler, InvestorsUnderground, AllPennyStocks, MarketClub, Marketbeat.com, Louis Navellier, Jim Cramer, Jason Bond and Stock Up Featured reported earlier on Tilray Brands Inc. (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Recent research presented at a conference in Hawaii indicates that individuals who contracted COVID-19 and who had used cannabis experienced more favorable outcomes and a reduced mortality rate compared to those who didn’t. These findings were shared during a presentation at the annual meeting of the American College of Chest Physicians (CHEST).

To carry out the research, a team of scientists scrutinized the medical records of more than 320,000 patients collected from the U.S. National Inpatient Sample, a database monitoring hospital admissions and outcomes. Any patients under the age of 18 years old or those with incomplete information were excluded from the study. Among the patients surveyed, only 1% — 2,603 patients — reported cannabis use.

These patients were classified into two groups based on their cannabis usage. To ensure comparability, the data from the study was employed to match cannabis users with nonusers in a one-to-one ratio based on factors such as gender, race, age and 17 other comorbidities, including chronic lung conditions. The research findings revealed a significant contrast between marijuana users and nonusers, with cannabis users displaying a notably lower mortality rate (2.9% versus 13.5%). Furthermore, cannabis users experienced significantly fewer COVID-19 complications such as multiorgan failure, acute respiratory distress syndrome and intubation.

The analysis brought to light that, on univariate assessment, cannabis users exhibited notably lower rates of intubation (6.8% versus 12%), acute respiratory distress syndrome (2.1% versus 6%), acute respiratory failure (25% versus 52.9%), severe sepsis resulting in multiorgan failure (5.8% versus 12%), in-hospital cardiac arrest (1.2% versus 2.7%) and mortality (2.9% versus 13.5%). The authors underlined the clinical implications of these findings and urged further exploration of the potential association between COVID-19 outcomes and marijuana use.

Research into potential links between marijuana and COVID-19 has been relatively scarce. In 2022, a study found that among patients hospitalized with COVID-19, cannabis users exhibited milder COVID-19 symptoms and markedly improved health results. Another study conducted the same year also indicated that marijuana use was associated with a reduced risk of contracting COVID-19, though it was also correlated with more severe infections.

Additionally, in 2022, researchers from the University of Oregon conducted a laboratory study that suggested marijuana compounds could prevent COVID-19 infection in human cells. These findings have prompted further investigations into cannabis as a potential treatment for COVID-19.

The recent study, titled “Exploring the Relationship Between Cannabis Smoking and COVID-19,” has been published in this month’s supplement to the peer-reviewed “CHEST” Journal.

This study, together with more scientific literature that is becoming available, gives further credence to the concept of medicinal marijuana and encourages entities such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) to keep developing more medical cannabis products for their clients.

Tilray Brands Inc. (TLRY), closed Friday's trading session at $1.84, off by 3.6649%, on 13,296,113 volume. The average volume for the last 3 months is 273 and the stock's 52-week low/high is $1.50/$5.12.

The QualityStocks Company Corner

Diamond Lake Minerals Inc. (OTC: DLMI)

The QualityStocks Daily Newsletter would like to spotlight Diamond Lake Minerals Inc. (OTC: DLMI).

Diamond Lake Minerals (OTC: DLMI), a leading multistrategy operating company specializing in the development and support of digital assets and SEC-registered security tokens, has announced a new strategic advisor: Agnes Budzyn. A successful entrepreneur and currently managing parter at Bluedge Ventures, Budzyn brings a  wealth of experience in blockchain, digital assets and traditional finance to her new role. During her career, Budzyn spent more than a decade in traditional finance, including a significant role at BlackRock, one of the largest investment management firms in the world. She was also a member of the leadership team at ConsenSys, a key player in the Ethereum ecosystem, where she worked on bridging the gap between traditional finance and emerging blockchain solutions. Budzyn has spent the last five years sharing her expertise with multiple businesses on a global scale in board member and advisory positions. Her experience includes technology enablement, digital assets, revenue generation strategies, and overall business transformation, particularly as companies grow or seek strategic funding. Budzyn currently serves on the board of directors at the Biden Institute, the FTSE Russell Digital Asset Advisory Committee and the Yale Club Audit Committee. Budzyn joins other DLMI board members Anthony Scaramucci, Larry Namer, Andrew Fromm, Brandon Fugal, Raul Leal and Michael Malik Sr. Diamond Lake Minerals is committed to creating a board that reinforces its commitment to innovation and excellence in the digital asset and security token industry.

"We are privileged to welcome Agnes Budzyn to our advisory board," said Diamond Lake Minerals CEO Brian J. Esposito in the press release. "Her expertise and deep understanding of blockchain, digital assets and finance align perfectly with our mission at Diamond Lake Minerals. We believe her insights will be invaluable as we continue to lead the way in the digital asset and security token space. Agnes's commitment to excellence is evident, and we look forward to a fruitful collaboration."

To view the full press release, visit https://ibn.fm/GLY9f

Diamond Lake Minerals Inc. (OTC: DLMI) is a multi-strategy operating company offering traditional investors an entry point to the future of digital securities. The company’s goal, through its established M&A roadmap, is to responsibly innovate and develop promising businesses that are likely to benefit from the ongoing shift toward digital assets. Through this approach, Diamond Lake Minerals provides traditional investors an opportunity to gain exposure to the emergence of regulated digital securities through a more familiar investment vehicle – the purchase of stock.

Founded in 1954 and headquartered in Salt Lake City, Diamond Lake Minerals is positioning itself as a leader in the digital asset and security token space. The company’s mission is to bring back to the public markets timeless business principles focused on healthy, sustainable growth and strong earnings with a goal of creating value for stakeholders in the modern digital world.

Diamond Lake Minerals believes the future of financial markets is set to be revolutionized by tokenization. Tokenization refers to the use of digital assets that can be traded via protocols with instantaneous settlement and reduced fees, eliminating the need for traditional clearing or settlement processes. Beyond efficiency, the emerging landscape emphasizes transparency, liquidity and security in asset management and investment.

With the backing of Esposito Intellectual Enterprises and its 20+ years of experience, Diamond Lake Minerals has access to the expertise of 110+ companies and 200+ joint ventures, along with knowledge spanning 25+ industries. The company is creating a vertically integrated ecosystem that encompasses various high-growth sectors. This integration aims to maximize operational efficiencies and profitability across all business units.

Products & Services Portfolio

Diamond Lake Minerals, guided by its strategic partnerships and future roadmap, envisions a diverse portfolio across multiple industries, as shown in the overview below. The company is poised to redefine the conglomerate model for the 21st century, with a focus on vertical integration, digital securities and sustainable growth.

Its target market segments include:

  • Fashion: DLMI seeks stakes in brands blending timeless aesthetics with tech influences.
  • Beauty: DLMI eyes partnerships with innovators elevating beauty through sustainable practices.
  • Real Estate: DLMI aims for interests in ventures modernizing property transactions via blockchain.
  • Hospitality: DLMI’s vision includes associations with enterprises enhancing guest experiences via tech integration.
  • Liquor: DLMI aspires to collaborate with unique distillers merging tradition and innovation.
  • IoT: DLMI intends to invest in solutions seamlessly connecting the digital and physical worlds.
  • Wireless: DLMI envisions stakes in wireless tech optimizing global communication.
  • Technology: DLMI plans to back pioneers driving the next tech revolution.
  • Maritime: DLMI seeks partnerships in maritime solutions emphasizing green initiatives.
  • Aviation: DLMI’s strategy includes holdings in aviation innovators focusing on efficiency.
  • Aerospace: DLMI aims to support ventures pushing boundaries in space exploration.
  • Education: DLMI collaborates with platforms revolutionizing learning through tech.
  • Charity: DLMI eyes alliances with charitable entities leveraging transparency via blockchain.
  • Healthcare: DLMI foresees investments in healthcare tech personalizing patient care.
  • TV: DLMI intends stakes in TV platforms innovating content delivery.
  • Film: DLMI aspires to support filmmakers merging storytelling with immersive tech.
  • Music: DLMI plans interests in music ventures amplifying artists through digital platforms.
  • Entertainment: DLMI targets stakes in platforms redefining entertainment paradigms.
  • IP: DLMI envisions collaborations safeguarding intellectual properties via tech solutions.
  • Data Management: DLMI seeks ventures optimizing data utilization and insights.
  • Data Storage: DLMI’s roadmap includes alliances with secure data storage solutions.
  • Streaming: DLMI intends to back streaming platforms prioritizing user experience.
  • Real World Assets: DLMI eyes investments translating tangible assets into digital value.
  • Gold & Silver: DLMI aims for stakes in platforms digitizing precious metal trading.
  • Sports: DLMI envisions collaborations enhancing sports experiences via tech integration.
  • Sports Technology: DLMI seeks ventures revolutionizing athlete performance and fan engagement.
  • Water: DLMI plans to back solutions ensuring water sustainability and accessibility.
  • Water Treatment: DLMI targets investments in eco-friendly water purification technologies.
  • Animation: DLMI eyes stakes in animation houses blending art with cutting-edge tech.
  • Studio Production: DLMI’s vision includes support for studios transforming content creation.
  • Consumer Products: DLMI seeks partnerships with brands prioritizing consumer-centric innovations.
  • Collectables: DLMI envisions collaborations with platforms digitizing unique collectibles.
  • Digital Assets: DLMI aims to invest in ventures maximizing the potential of digital ownership.
  • Web3: DLMI aspires to back pioneers ushering in the decentralized web era.
  • Identity Management: DLMI eyes solutions prioritizing user identity security in the digital space.
  • Media & Journalists: DLMI seeks alliances promoting unbiased reporting and content democratization.
  • Metaverse: DLMI envisions stakes in ventures crafting immersive virtual universes.
  • Space Economy: DLMI targets investments in ventures monetizing space exploration.
  • Modular Homes: DLMI plans interests in solutions revolutionizing home construction.
  • Financial Technology: DLMI seeks partnerships modernizing financial transactions.
  • Gaming: DLMI aims to back game developers enhancing user immersion.
  • Travel: DLMI eyes collaborations transforming travel experiences through tech.
  • Health & Wellness: DLMI’s strategy includes investments in holistic health tech solutions.
  • Augmented Reality: DLMI envisions stakes in AR platforms blurring reality and digital.
  • AI: DLMI seeks to support AI innovations humanizing tech interactions.
  • Esports: DLMI targets investments in platforms amplifying esports experiences.
  • Construction: DLMI plans to back ventures modernizing construction practices.
  • Virtual Reality: DLMI intends stakes in VR platforms offering alternate realities.
  • Retail Tech: DLMI envisions collaborations digitizing retail experiences.
  • Biotechnology: DLMI seeks ventures pushing boundaries in biotech innovations.

Market Opportunity

According to Diamond Lake Minerals’ business plan executive summary, the market for digital securities is projected to grow from $10 billion in 2022 to $1 trillion by 2028, a CAGR of 45% for the forecast period.

The global blockchain market value is expected to grow from an estimated $3 billion in 2020 to $39.7 billion by 2025, marking a CAGR of 67.3% for the period. Valued at $2.28 billion in 2021, the Security Token Offerings market is projected to grow at a CAGR of 19%. This growth is expected to be driven by the rising adoption of tokenization and the increasing prominence of STOs, especially in North America.

In addition, the global investment management market is projected to grow from a value of $100 trillion in 2020 to $178 trillion by 2025, recording a CAGR of 7.2% over the period.

Management Team

Brian J. Esposito is CEO of Diamond Lake Minerals. As founder and CEO of Esposito Intellectual Enterprises LLC, he brings over 20 years of diverse experience in sectors like manufacturing, technology, music and real estate, and is known for his global executive networking and balance sheet optimization skills.

Michael Reynolds is President and Director of Diamond Lake Minerals. With 35 years in private finance and M&A, he has been instrumental in growing companies like Herbalife through reverse acquisition, as well as elevating JB Oxford to $120 million in revenue. His expertise in operational management and business development ensures professional solutions for clients’ business interests.

Jon Karas is DLMI’s senior transaction and investment executive. As the CEO and co-founder of Akon Legacy Ventures, he structured, negotiated and closed numerous transactions focused on innovation and social impact in smart cities, blockchain, agriculture, mining and technology. He co-founded and led multiple companies in media and entertainment and was the driving force behind the development, financing and production of a broad range of film and television content.

Advisory Board

Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital and Chairman of SALT, brings to Diamond Lake Minerals unparalleled expertise in finance, technology and business strategy. He is expected to be instrumental in shaping DLMI’s strategic direction as the company continues to redefine the future of traditional and digital securities.

Larry Namer, Founder of E! Entertainment TV and President of Metan Global, boasts a remarkable career spanning more than half a century. He is an esteemed veteran of the entertainment industry, renowned for his influential contributions to cable television, live events, music and new media. He also leads LJN Media, a consulting firm known for its cross-industry expertise in technology, business and finance.

Andrew Fromm is a seasoned CEO and consultant with a focus on music publishing. He is known for his expertise in asset sales, songwriting and artist development. His extensive network extends beyond the music industry, showcasing his versatility and authority in the field.

Brandon Fugal is the Chairman of Colliers International in Utah and a former EY Entrepreneur of the Year. He has co-founded multiple ventures, including Coldwell Banker Commercial Advisors, Cypher, Axcend and Texas Growth Fund, and he is a recognized authority in real estate and entrepreneurship.

Michael Malik Sr. is a Detroit-based entrepreneur with a $750 million net worth, known for his pivotal role in legalizing gambling and developing major casino projects across the U.S., including Detroit’s MotorCity Casino and various Native American gaming ventures. He brings to Diamond Lake Minerals a wealth of experience and a proven track record in the gaming, sporting and entertainment industries spanning over five decades.

Raul Leal is an experienced CEO in the hospitality sector, known for his visionary leadership at SH Hotels & Resorts and former role at Virgin Hotels, where he secured over $500 million in funding and revolutionized guest experiences.

Agnes Budzyn, an accomplished entrepreneur and CEO of Bluedge Ventures, brings to the company a rich history in traditional finance and blockchain technology, serving on various global boards and committees. She has been recognized by the World Economic Forum and numerous institutions for her expertise and contributions to bridging legacy finance with emerging digital asset infrastructure.

Diamond Lake Minerals Inc. (OTC: DLMI), closed Friday's trading session at $3.49, up 2.2711%, on 100 volume. The average volume for the last 3 months is 84,394 and the stock's 52-week low/high is $0.35/$3.50.

Recent News

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF)

The QualityStocks Daily Newsletter would like to spotlight Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) .

Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF), a leading gold explorer in the Guiana Shield, is reporting positive drill results from its ongoing infill and deep drilling programs at its Guyana-based Oko West Project. According to the report, drilling for the conversion of Inferred category to Indicated category resources continued within the MRE pit constraint and continued to deliver expected high-grade intersects. In addition, drilling below the MRE pit shell has continued for the purpose of defining an underground resource. Based on the positive results of the drilling program, Reunion Gold has decided to delay the delivery of a preliminary economic assessment ("PEA") until the end of second quarter 2024. The report noted that the infill drilling program is designed to upgrade the inferred resources within the Mineral Resource Estimate ("MRE") pit shell to an Indicated mineral resource category, and the deep drilling program is aimed at testing and defining the potential for an underground resource at depths greater than 500 meters below surface.

In addition to the ongoing drilling at the Kairuni zone of its Oko West Project, Reunion Gold continues to advance its exploration programs on the remainder of the Oko West Prospecting License, including implementing ground magnetics and IP geophysical surveys, RC drill programs and follow-up diamond drill programs. "We are very encouraged with the results of the deep drilling program to date, which indicate the potential for a high-grade zone at depth," said Reunion president and CEO Rick Howes in the press release. "With these results, we see the potential to add significant value as a combined open pit and underground project, and therefore we intend to continue the depth extension drilling program and delay the release of the PEA to allow for inclusion of an underground resource and evaluation of combined open pit and underground option to the PEA study, which we would expect to release in Q2 of 2024."

To view the full press release, visit https://ibn.fm/MSBOy

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) is a leading gold explorer in the Guiana Shield, South America. In early 2021, the Company announced an exciting new greenfield gold discovery at its Oko West project in Guyana, where, after 22 months of resource definition drilling, the Company has announced an initial Mineral Resource Estimate (MRE) containing 2.475 Moz of gold in Indicated resources at 1.84 g/t and 1.762 Moz of gold in inferred resources at 2.02 g/t contained within a pit shell outline. Preliminary metallurgy results performed by the company, consisting of 8 bottle roll tests obtained strong results, averaging just under 90% recoveries on average. The Company is continuing with additional development activities at Oko West, including environmental base line studies and additional metallurgical work relating to the delivery of a PEA by year end 2023. In addition, Reunion Gold is currently exploring several priority targets in the Oko West project area on which the company feels there is good potential to add additional resource ounces. This includes the opportunity to grow the initial mineral resource estimate (MRE) released on June 13, 2023, and to discover additional gold ounces at Oko West outside of the resource area.

The Guiana Shield remains one of the most prospective exploration locations globally for the discovery of world class orogenic gold deposits. The shield, including both Guyana and Surinam, contain large relatively underexplored greenstone belts, from which Reunion Gold expects many more significant gold discoveries could emerge in the coming years.

Oko West Project

Reunion Gold’s Oko West Project is a brand-new gold discovery in northwest Guyana located within the historical Oko gold district. Alluvial gold has been mined from the Oko district since the turn of the century, but very little primary gold has been mined or even explored for to the best of the company’s knowledge. The project comprises a prospecting license with an area of approximately 44 square kilometers and is 100% held by Reunion’s Guyanese subsidiary.

In 2020, Reunion Gold’s geochemical survey, trenching and initial 1000 m drill program discovered and confirmed the presence of gold mineralization in this Orogenic gold system. The gold occurs in the eastern edge of the project area, along a 6km long sheared contact between a granitoid intrusion and a meta volcanic-meta sedimentary rock package. The MRE is located within the Kairuni zone, which represents the northern most 1.9 km of the 6 km long contact.

“We are advancing our Oko West project along two tracks. The first is to advance the exploration programs outside of the Kairuni zone, aimed at outlining and discovering additional gold mineralization within our Prospecting License. On this front, I am very excited by the results from the initial Scout RC Geochem drill program that is defining new targets west of our Kairuni zone,” Rick Howes, President and CEO of Reunion Gold, stated in a recent news release. In addition to the targets west of the Kairuni zone, the company has also commenced exploration work on the southern ~ 4 km of the same sheared contact that hosts the Kairuni zone MRE. In addition, the company feels that the MRE marks the size of the Kairuni resource at a point in time and that there is good potential to continue to grow the resource. The MRE remains open at depth below the resource pit outline in the block 4 area and also to depth and along strike in the block 5 and 6 areas. In addition to the exploration programs, the second strategic track is to rapidly advance the Kairuni zone along the path to development. To that end the company is moving forward with the engineering and other studies, including more detailed metallurgical studies, that will support the release a PEA on the Kairuni zone by year end 2023 The company feels that the rapid advancement of development of Kairuni zone MRE, while in parallel continuing to explore for additional ounces on the project, is the best path to try and maximize shareholder value in the shortest period of time.

Guyana

Guyana boasts a long history of mining gold, bauxite, diamonds and manganese. Still, the greenstone belts of the Guiana Shield remain relatively unexplored when compared to the analogous regions of the West African Shield (Birimian), which, according to geological evidence, was once connected to the Guiana Shield, forming a contiguous craton prior to the Mesozoic period.

Despite a historical lack of accessibility and low exploration intensity, several significant large-scale projects have emerged in the Guiana Shield, including Aurora, Oko West, Oko Main, Toroparu and Omai. Guyana is English speaking with a British based parliamentary and legal system and boasts the world’s fastest growing economy on the back of significant offshore oil discoveries by Exxon and its partners. It is expected that a significant amount of the revenues from oil production will be invested in improving the infrastructure, education and health care and agriculture within the country.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, called 2022 the “strongest year for gold demand in over a decade.” Annual gold demand jumped 18% YoY due to “colossal central bank purchases, aided by vigorous retail investor buying and slower ETF outflows.”

Despite this spike in demand, total annual gold supply increased by just 2% in 2022, halting two years of successive declines but failing to challenge 2018 highs. This supply-demand imbalance could provide a favorable market environment as Reunion Gold continues to advance drilling programs at its 100%-owned Oko West Project.

Management Team

Successful exploration and the discovery of significant deposits in any given region require immense amounts of local knowledge and experience. This is the principle around which Reunion Gold has built its management team. In total, the company’s leadership boasts over 225 years of combined experience in the Guiana Shield.

David Fennell is the Executive Chairman of Reunion Gold, a position he has held since the company’s inception in 2003. He has 40 years of experience in the mining industry. He received a law degree from the University of Alberta in 1979 and practiced law until he founded Golden Star Resources Ltd. in 1983. During his term as President and CEO, Golden Star became one of the largest and most successful exploration companies. While at Golden Star, he was instrumental in the discovery and development of the Omai Gold Mine in Guyana and the Gross Rosebel Mine in Suriname. In 1998, Mr. Fennell became Chairman and CEO of Hope Bay Gold Corporation. He held this position through the merger of Hope Bay and Miramar Mining Corporation and remained as Executive Vice-Chairman and Director for the combined entity until its takeover by Newmont Mining Corporation in 2008. Mr. Fennell is currently a member of the board of directors of G Mining Ventures Corp. and Sabina Gold & Silver Corp.

Rick Howes, P.Eng., is the company’s President and CEO. He is a seasoned mining executive with over 39 years of experience in the mining industry, most recently as CEO of Dundee Precious Metals. Mr. Howes has extensive operating, technical and project development experience in both underground and open pit mines throughout Canada and internationally. In 2009, Mr. Howes joined Dundee Precious Metals, where, as VP and General Manager, he led the transformation of the Chelopech Mine in Bulgaria to reach world-class levels of performance. He became COO in 2011 and oversaw several significant growth capital development projects, including the expansion of the Chelopech Mine, the upgrade and expansion of the Tsumeb Smelter in Namibia and the development of the greenfield Ada Tepe open pit gold mine in Bulgaria. He was appointed CEO in April 2013, leading Dundee’s transformation from a junior gold producer to a multi-asset mid-tier gold producer generating strong free cashflow and solid returns to shareholders. Mr. Howes has been recognized as a visionary leader in mining, organizational innovation and transformation and was recognized as the Outstanding Innovator of 2016 by the International Mining Technology Hall of Fame.

Alain Krushnisky is the CFO of Reunion Gold. He brings to the company years of experience in the mining sector, including 10 years with Cambior Inc. (now IAMGOLD) in capacities such as Vice-President and Controller. Since 2004, Mr. Krushnisky has been doing consulting work for various publicly listed exploration and mining companies. He graduated from the University of Ottawa in 1983 with a bachelor’s degree in commerce and is a Chartered Professional Accountant.

Justin van der Toorn is the company’s VP Exploration. He is an exploration geologist with 18 years’ experience in the minerals industry, leading and managing exploration teams from grassroots activities through to discovery and resource definition drilling. Mr. van der Toorn’s previous experience has been in a range of commodity and deposit styles, including extensive work in Carlin-style gold, low- and high-sulphidation epithermal, porphyry and orogenic gold systems. He holds an MSci degree in Geological Sciences from the Royal School of Mines, Imperial College London. He is registered as a Chartered Geologist (CGeol) of the Geological Society, and a European Geologist (EurGeol) by the European Federation of Geologists.

Doug Flegg is the company’s business Development advisor. Doug has over 35 years’ experience in mining and mining finance with senior positions in research, portfolio management and global equity sales. Previously, Mr. Flegg was Managing Director Global Mining Sales with BMO Capital Markets where he was involved in raising $35 billion in over 200 corporate financings. Since 2016 he has been providing business development, strategic, and financing advice to corporate mining clients. Mr. Flegg also has a B.Sc. in Geology, work experience as a geologist and an MBA from Queens University.

Reunion Gold Corp. (OTCQX: RGDFF), closed Friday's trading session at $0.3197, up 8.6306%, on 52,180 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.50/$.

Recent News

Prospera Energy Inc. (TSX.V: PEI) (FRA: OF6B) (OTC: GXRFF)

The QualityStocks Daily Newsletter would like to spotlight Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) .

International Energy Agency ("IEA") forecasts record oil production in Canada, global demand and prices expected to rise as Russia and Saudi Arabia cut production

Prospera Energy operates 42,000+ cumulative acres, estimates approximately 8% of over half a billion available barrels was recovered using traditional vertical well technology

The company completed Phase 1 of restructuring plan, production expanded from 80 to 1,200 BOE and NPV increased from $3 million to $72 million

Phase 2 focuses on horizontal well transformation, piloting an enhanced oil recovery application, executing liability management objectives, and furthering ESG initiatives

The company recently completed four horizontal wells of ten-well multi-pad infill drill program, to start next set of four horizontal wells by end of September

Canada is expected to hit an all-time high for oil production this year, according to the International Energy Agency ("IEA") (https://ibn.fm/8UhdV). The agency forecasts that demand will rise by 1.9 million barrels per day (mb/d) to a record 101.7 mb/d as China lifts COVID restrictions. Accordingly, prices are set to hit $100 a barrel amid production cuts by Saudi Arabia and Russia to create a "substantial market deficit", according to the agency (https://ibn.fm/3bCnu).

Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a Canada-based public oil and gas exploration, exploitation, and development company, is rapidly transforming into a sustainable energy producer with a focus on efficient hydrocarbon development, recovery, and production practices. The company operates more than 42,000 cumulative acres across several core properties in Western Canada, including Cuthbert, Luseland, and Heart Hills in Saskatchewan: and Red Earth and Pouce Coupe in Alberta. According to management estimates, approximately 8% of over half a billion barrels was recovered using traditional vertical well technology.

Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) is a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western Canada. The company uses its experience to develop, acquire and drill assets with potential for primary and secondary recovery.

Prospera is primarily focused on optimizing hydrocarbon recovery from legacy fields through environmentally safe and efficient reservoir development methods and production practices. It is in the midst of a three-stage restructuring process aimed at prioritizing cost effective operations while appreciating production capacity and reducing liabilities.

The company is based in Calgary, Alberta, Canada.

Operations

Prospera’s core properties include more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta. In total, the company estimates that there are half a billion barrels of oil in place at these sites accounting for 20+ years of forward project lifespan, with as little as 8% of total reserves having been recovered via legacy vertical well technology.

Restructuring Initiative

In 2021, Prospera enacted a top-down reorganization. The early results of these efforts were on display in May 2023, when the company reported a three-fold year-over-year increase in annual revenue for 2022 alongside drastically reduced operating costs and record-high cash flow from operations.

Prospera noted in the news release that it has positioned itself in 2023 to execute the second phase of its development plan aimed at increasing production through medium-oil development in Alberta and leveraging horizontal wells to capture the significant remaining reserves in Saskatchewan.

During the company’s investor summit in August 2023, Prospera CEO Samuel David provided more information regarding this three-phase strategy:

Phase I

Prospera completed the first phase of its restructuring by optimizing operations at its existing assets and addressing legacy arrears and non-compliance issues.

At the beginning of this transformation, the company was producing just 80 barrels of oil equivalent (BOE) per day. In Q4 of last year, Prospera peaked at nearly 1,200 BOE per day. Its breakeven is around 500 barrels per day, illustrating the opportunity for free cash flow. This prospect has driven Prospera’s capital development and optimization in recent quarters.

After a temporary slowdown in production due to harsh winter conditions, Prospera is currently producing about 800 BOE per day and anticipates an additional 300-500 barrels of daily production following the completion of ongoing site maintenance work.

This sustained increase has pushed the company’s NPV from roughly $3 million prior to the restructuring efforts to approximately $72 million today.

In an effort to build on this progress and maximize its available resources, Prospera piloted two horizontal reentries to assess a potential horizontal well transformation at its properties.

Phase II

Following up on the optimization efforts of Phase I, Prospera aims to commence a horizontal well transformation at its properties in the coming months. Based on its pilot wells from Phase I, the company has proposed 10 horizontal well locations at its Cuthbert and Heart Hills properties.

Prospera has likewise proposed eight medium light oil direction wells at its Alberta property, and it is exploring strategic acquisitions aimed at expanding its core area and diversifying its product mix.

Other facets of Phase II include piloting an enhanced oil recovery (EOR) application and continuing to execute its liability management goals and ESG initiatives. Prospera has already abandoned 60 vertical wells as part of its three-year LMR plan to reclaim surface land and reduce the environmental footprint of its operations.

Phase III

Beginning next year, Phase III of Prospera’s corporate redevelopment strategy will focus on continuing the company’s horizontal modular development to appreciate production and optimize recovery of remaining reserves. Prospera intends to implement full-scale EOR applications based on the results of its Phase II pilot program, which is forecast to optimize recovery by greater than 10%.

Prospera also intends to continue its acquisition strategy to diversify its product mix. Its goal, as detailed by in August 2023 investor summit, is to attain 50% light oil, 40% heavy oil and 10% gas – all while continuing to eliminate carbon emissions as part of its existing ESG initiatives.

Poised for Growth

Following its transformational efforts in 2022, Prospera is poised to achieve record growth in 2023. The company has forecast significant reductions in production costs through 2024, alongside sizable increases in daily production.

Prospera is currently exploring strategic acquisition targets to potentially increase its production beyond 5,000 BPD while expanding its reserve base to a billion barrels.

Market Opportunity

While the oil and gas industry faces long-term geopolitical and macroeconomic uncertainty, there is a clear trend to secure supply in the short term. According to Deloitte, the global upstream industry ended 2022 with some of the highest free cash flows on record, driving reinvestment in hydrocarbons and overall investment in clean energy.

The Energy Information Administration recently forecast a dip in global oil inventories over each of the next five quarters, placing upward pressure on oil prices. The agency further forecasts a YoY increase in fuel consumption, exacerbating the effects of OPEC+ production cuts that are set to remain in place through 2024.

For Prospera, these forecasts are promising. The company aims to build on its recent financial growth in the coming months (Prospera reported a three-fold YoY increase in revenue to $13.9 million in 2022), hitting a projected $57 million in total revenue by the end of 2024 while working to expand its core area holdings through accretive M&A transactions.

Leadership Team

Prospera is led by a team with extensive, diverse petroleum industry experience spanning both reservoir management and operations of oil and gas assets. The team boasts a proven track record of reorganizing companies, structuring financing arrangements and positioning for growth.

Samuel David is the company’s President and CEO. He brings to Prospera over 32 years of experience in operation, development and management of oil and gas assets and companies. Mr. David holds a B.Sc. in Mechanical Engineering and a B.A. in Economics from the University of Calgary. His background consists of both engineering and executive management experience with majors Petro-Canada, AEC Oil & Gas (now EnCana / Cenovus) and Husky Energy, as well as founding and operating juniors Ventura Energy and First West Petroleum. Mr. David has proven expertise in corporate planning, production, reservoir engineering, depletion strategies, EOR, property evaluations, acquisitions and divestitures.

George Magarian is VP Subsurface for Prospera. He is a professional petroleum geologist (APEGA) with over 36 years’ experience in the Western Canada Sedimentary Basin. After graduating with an Honors B.Sc. degree in Earth Science from the University of Waterloo, Mr. Magarian spearheaded many successful exploration programs, conducted evaluations for improved recovery schemes and assessed/exploited unconventional oil reservoir opportunities. He has held roles of increasing responsibility, from exploration geologist at oil industry major Petro-Canada and intermediates Anderson Exploration and Jordan Petroleum, to geoscience manager and VP exploration at junior companies Ionic Energy, Gentry Resources and Westfire Energy.

Chris Ludtke is the company’s VP Finance & Accounting. He is a high functioning finance leader with extensive expertise in finance, budgets and planning, accounting, economic evaluation, management, governance and sound decision making. Mr. Ludtke has 20 years of experience within the oil and gas, clean energy and renewables industries, including 12+ years working for Husky Energy before moving into an executive role in the junior oil and gas and hydrogen space. He graduated from the University of Lethbridge (Bachelor of Management) and is a Chartered Professional Accountant in the Province of Alberta.

Matthew Kenna is the CFO of Prospera. He has over 30 years’ experience leading organizations and helping them expand, drive efficiencies and grow profitability. Mr. Kenna is a professional accountant (CPA, CMA) and spent 15 years heading up the financial and operating departments at KUDU Industries, where he fostered financing arrangements, client relationships and manufacturing teams to take the organization from $35M to $150M in revenue. He has extensive experience turning companies around, growing them and building efficient organizations.

Prospera Energy Inc. (OTC: GXRFF), closed Friday's trading session at $0.08142, up 1.775%, on 5,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.048/$0.134.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma ("GBM"). "The Texas-based company has clinical trial sites operating in the U.S., Italy, France, Spain, and Switzerland, to evaluate Berubicin's performance against standard of care alkylating chemotherapy agent Lomustine for treating recurrent GBM. GBM has been generally untreatable by anthracyclines because of their inability to cross the blood-brain barrier, but Berubicin is believed to be able to cross the barrier and directly target central nervous system tumors. CNS Pharmaceuticals' progress in enrolling patients for its potentially pivotal, global clinical trial indicates the company is on track to not only complete enrollment by the end of the year, but also to issue its planned futility interim analysis," a recent article reads. "We are pleased to achieve this landmark milestone. Importantly, this takes us one step closer to bringing the study across the finish line and potentially offering an effective treatment in GBM that is safe and well tolerated," CNS Pharmaceuticals CEO John Climaco is quoted as saying.

To view the full article, visit https://ibn.fm/BI8W3

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $2.02, up 2.0202%, on 207,971 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6105/$6.597.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform. The company continues to devote an increasing proportion of its resources and focus toward research and development ("R&D") as part of its overall goal to establish areas of investigation for commercial pursuits and reduce risks of the unknown for both commercial and regulatory endeavors. "In the three months ended May 31, 2023 (‘Q3 2023'), for example, the company increased its R&D expenses 118% year over year to $1.64 million from $752,095 in Q3 2022. A recent Zacks Investment Research report attributed this expenditure to Lexaria's multiple DehydraTECH investigational research programs then underway, including analysis and execution of hypertension, nicotine and diabetes studies. The report also lauded the company's efficient use of capital, which allowed its R&D activities to expand into new preclinical work, including hormone therapy and dementia," a recent article reads. "While still at an early stage, these programs could be excellent partnership opportunities that will support further growth and potentially provide growth capital," reads the report. "Research efforts around these indications help further characterize DehydraTECH-CBD and its advantages compared with traditional delivery methods."

To view the full article, visit https://ibn.fm/p4kgV

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $1.18, up 9.2593%, on 100,802 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6488/$3.5953.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a strategic metals supply chain-focused enterprise, has entered a multi-decade lease agreement with the administrators of the England Airpark in Alexandria, Louisiana. Under the agreement, Ucore will build and operate a Strategic Metals Complex ("SMC") where it will separate and produce REEs and oxides that are deemed critical to computer technology-based industries. "Currently, REE mining and refining are controlled by The People's Republic of China to a degree that approaches a virtual monopoly. The European Union imports 98% of its REE supply from China and the United States gets 78% of its REE supply from China… Ucore's advancing SMC complex in Louisiana is central to the company's plan to build that Western supply chain, starting with the refining of mined product," a recent article reads. "The overall state and local support we are receiving for the establishment of one of the first modern rare earth element processing facilities in North America has been an amazing experience… We are diligently working to execute a Louisiana project that has the potential to significantly enhance the manufacturing landscape across North America as the world shifts to electrification," Ucore VP and COO Mike Schrider is quoted as saying.

To view the full article, visit https://ibn.fm/J02A6

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is a critical metals (“CM”) separation technology company executing an ESG-centered plan toward establishing a comprehensive North American critical metals supply chain. The company has developed a transformative commercial-ready technology, RapidSX™, for separating and purifying critical metals. Ucore intends to deploy this technology in pursuit of a CM supply chain independent of China for Western original equipment manufacturers (“OEMs”), most notably in the automotive and renewable energy industries.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. Its initial focus is on processing heavy and light rare earth elements (“REEs”), disrupting a supply chain that is dominated by China.

China currently controls about 80% of the world’s access to REE mining projects and over 90% of the world’s REE processing capabilities, and it produces about 95% of the goods containing REE components.

 

Ucore is working to scale Western supply needs by establishing REE separation and rare earth oxide (“REO”) production capabilities in cooperation with strategic upstream supply and downstream offtake partnerships. The company, along with its industry partners, aims to unlock access to Western REEs for current consumer, energy, manufacturing and military sectors.

By 2025, Ucore expects to commercially separate U.S.-friendly sources of REEs and supply OEMs with REOs required to produce rare earth permanent magnets (“REPMs”) – the essential component of electric motors and generators required to support the world’s transition to electrification and sustainable energy sources.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

The company has three initial U.S.-friendly feedstock agreements in place for the Louisiana complex, along with multiple developing offtake agreements. It received a C$16 million+ incentive package offer from Louisiana Economic Development to support construction of the SMC.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Friday's trading session at $0.46, even for the day, on 45,502 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.43/$1.15.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

GEMXX Corp., producer and distributor of gold and gems, draws on its own mining assets to manufacture its colorful jewelry, unique in the jewelry industry, and is the leading producer of top-quality finished Ammolite products.

GEMXX just completed its second clean-out and recording of gold production at its Snow Creek Mine site, yielding 172.3 ounces of gold from 18,000 cubic yards of material, resulting in 0.96 ounces per 100 cubic yards.

2023 gold production is a huge milestone for the company, as it looks to de-risk its revenues and complement its Ammolite production, and the company is on track to exceed its estimated gold production for the 2023 mining season

GEMXX (OTC: GEMZ), a publicly traded company specializing in producing and distributing gemstones and jewelry globally, is on track to exceed its estimated production for the 2023 mining season. This follows the recent successful completion of its second clean-out and recording of gold production at its Snow Creek Mine site, which yielded 172.3 ounces of gold from 18,000 cubic yards of material, resulting in 0.96 ounces per 100 cubic yards (https://ibn.fm/o5xVm).

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Friday's trading session at $0.06, even for the day, on 24,242 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.023/$0.998.

Recent News

GolfLync Inc.

The QualityStocks Daily Newsletter would like to spotlight GolfLync Inc.

GolfLync, seen as one of the hottest and fastest growing new golf apps in social media, has partnered with golfing sensation Eliezer Paul-Gindiri, nicknamed "Snappy Gilmore," whose distinctive single-handed golf swing stunned the golfing world in 2021. "GolfLync's many features, including its trademarked Virtual Golf Clubs(TM) (‘VGC'), private feeds, group chats, and personalized golf experiences, set it apart as the go-to social network for golfers of all levels. As Snappy Gilmore stated ‘Finding players is easy on GolfLync. Having my own Virtual Club allowing my followers access is great,'" a recent article reads. "Snappy is a Nigerian-American amateur golfer whose focus on health and wellness, combined with solid entertainment vibes, has generated ongoing buzz with the PGA Tour, PGA Tour of America, and various charitable causes. In a July 10th 2023, article, Sports Illustrated named Snappy Gilmore as one of ‘The Top Ten Social Media Stars in Sports.'"

To view the full article, visit https://ibn.fm/4g9hZ

GolfLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as “the social network for golfers,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.

 

Management Team

Noah DiPasquale is a co-founder and CEO of GolfLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of GolfLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News

chart

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion (NASDAQ: FNGR), a mobile services and data company, has filed a federal lawsuit against Capybara Research; the lawsuit alleges that Capybara maliciously published a defamatory article in a premediated attempt to move the public market for FingerMotion's stock lower to benefit from its previously announced short position. FingerMotion filed the complaint in the United States District Court for the Southern District of New York. FingerMotion is working with Mark R. Basile, Esq, and his securities and RICO litigation firm, the Basile Law Firm P.C., to investigate recent activities surrounding the company's stock performance as well as to take necessary legal action to prevent potential market participants utilizing unlawful means from further hurting FingerMotion shareholders. "We are committed to understanding what has been happening to our stock," said FingerMotion CEO Martin Shen in the press release. "This action was initiated to reel in any potential unlawful interference with our company's public market for its stock."

To view the full press release, visit https://ibn.fm/XDAEn

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Friday's trading session at $6.32, off by 5.2474%, on 2,466,671 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.01/$8.19.

Recent News

Renovaro BioSciences Inc. (NASDAQ: RENB)

The QualityStocks Daily Newsletter would like to spotlight Renovaro BioSciences Inc. (NASDAQ: RENB) .

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, will be spotlighted in webinar taking place today. The webinar is scheduled to start at 3 p.m. ET. Renovaro BioSciences CEO Mark Dybul will be featured in the webinar, which is titled "Future Health Tech: Challenges and Opportunities," and will provide key information about the company and its role as a leader in the health tech space. Those interested in joining the webinar can call in by dialing 1-507-473-4847 in the United States, then use the ID number 875 7586 1258.

To view international numbers, visit https://ibn.fm/0xFX7

To view the webinar,, visit https://ibn.fm/3vxFt

Researchers say they may have found a new and more efficient means of treating prostate cancer that reverses the cancer's resistance to treatment. Although treatment is fairly effective, prostate cancer can become resistant to treatment in some advanced cases and continue to grow despite low and even below-castrate level testosterone levels. Prostate cancer is the second most prevalent cancer type in American men after skin cancer, affecting around 288,300 men in the country and more than a million men globally every year. It has relatively favorable treatment outcomes, especially when the condition is diagnosed early. Many men have lived with the condition for decades without the need for treatment or showing symptoms. However, prostate cancer can become resistant to treatment. Recent research indicates that scientists have discovered that blocking cancer cells from using secret messages to commandeer white blood cells can reverse prostate cancer treatment resistance. In a recent small study, researchers found that blocking the secret messages shrank prostate tumors in some patients and prevented the tumors from growing in others, potentially opening up the door to more effective prostate cancer treatments.

Renovaro BioSciences Inc. (NASDAQ: RENB), formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.

RENB-DC11

Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

  • RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
  • RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (GDT) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
  • RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
  • RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
    LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

Renovaro BioSciences Inc. (NASDAQ: RENB), closed Friday's trading session at $3, off by 13.0435%, on 563,010 volume. The average volume for the last 3 months is 860,449 and the stock's 52-week low/high is $0.3928/$5.25.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

LG's South Korean mobile network operator LG U+ collaborated with KAIST (Korea Advanced Institute of Science and Technology) and Korea's Qunova Computing to advance 6G satellite networks using the power of D-Wave's quantum computing solutions

D-Wave's annealing quantum computer has helped the companies successfully develop seamless connectivity of ground-to-satellite links and inter-satellite links

D-Wave is the world's first commercial supplier of quantum computers and is helping customers apply practical quantum computing solutions to solve highly complex computational problems today

D-Wave Quantum (NYSE: QBTS) recently announced that LG U+, under the leadership of CEO Hyeon Sik Hwang, worked with the Korea Advanced Institute of Science and Technology ("KAIST") and Qunova Computing to advance the development of a groundbreaking 6G low-earth orbit ("LEO") satellite network. The network facilitates seamless connectivity of satellite-to-ground links ("SGLs") and inter-satellite links ("ISLs") that employ the power of D-Wave's quantum computing system, successfully optimizing the intricate network.

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $0.7939, off by 5.9694%, on 1,316,271 volume. The average volume for the last 3 months is 4.189M and the stock's 52-week low/high is $0.3962/$6.25.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is hosting an upcoming virtual key opinion leader ("KOL"); the event will focus on the current state of lung cancer treatments and the challenges facing patients. Titled  "Bringing Gene Therapy to the Fight Against Lung Cancer," the event is slated for Oct. 27, 2023, at 12:30 p.m. ET. During the event, Alexander I. Spira, MD, PhD, FACP, and director of the Virginia Cancer Specialists (VCS) Research Institute and the phase I trial program at Johns Hopkins Hospital will join Daniel Morgensztern, MD, a professor of medicine and the director of thoracic oncology at Washington University School of Medicine; both doctors are medical oncologists.

The discussion will be facilitated by Genprex chief medical officer Mark S. Berger, MD. According to the announcement, the event, which will include a Q&A session with audience members, will spotlight Genprex's lead product candidate REQORSA(R) (quaratusugene ozeplasmid) as a potential treatment for both non-small cell lung cancer ("NSCLC") and small cell lung cancer ("SCLC"). Following the event, a replay of the event will be available on the Genprex website.

To view the webinar, visit https://ibn.fm/7jjiY

To view the full press release, visit https://ibn.fm/zfY56

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Friday's trading session at $0.2999, off by 2.945%, on 334,466 volume. The average volume for the last 3 months is 421,559 and the stock's 52-week low/high is $0.2915/$1.94.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
480-374-1336

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .